Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma
Date
2019Journal
Blood AdvancesPublisher
American Society of HematologyType
Article
Metadata
Show full item recordSponsors
This work was supported by a research grant from Merck & Co., Inc.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067489028&doi=10.1182%2fbloodadvances.2019000191&partnerID=40&md5=cf00ca42f737dd7a6b55260e74069446; http://hdl.handle.net/10713/10677ae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2019000191
Scopus Count
Collections
Related articles
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
- Authors: Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S, KEYNOTE-183 Investigators.
- Issue date: 2019 Sep
- Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
- Authors: Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, Matsue K, Miyoshi M, Bleickardt E, Matsumoto M, Taniwaki M
- Issue date: 2017 Mar 10
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
- Authors: Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators.
- Issue date: 2019 Sep
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
- Authors: Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J
- Issue date: 2018 Nov 8
- Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
- Authors: Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG
- Issue date: 2018 Oct 15